JPRN-jRCT2080223114招募中1 期
Single-Dose and Multiple-Dose, Dose-Escalation Study with LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients with Mild Cognitive Impairment Due to Alzheimer's Disease and Mild to Moderate Alzheimer's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Healthy Participants Part A:
- •-Overtly healthy males or females as determined by medical history and physical examination
- •-Have a body mass index (BMI) between 18.0 and 32.0 kilograms per meter squared (kg/m2), inclusive
- •Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) [Part B and C]:
- •-Participants are at least 50 years old at screening
- •-Present with Mild Cognitive Impairment (MCI) due to Alzheimer's Disease (AD) or mild-to-moderate AD
- •-Have a caregiver/study informant who provides a separate written informed consent to participate
- •-Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator
- •-Positive florbetapir scan
排除标准
- •All Participants
- •-Are currently enrolled in a clinical trial involving an investigational product or off-label use of a drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •-Have known allergies to LY2599666, solanezumab, or any related compounds or components of the formulations, or have a history of significant atopy
- •-Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
- •-Have an abnormal blood pressure as determined by the investigator
- •-Have significant allergies to humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisone
- •-Require treatment with other monoclonal antibodies
- •Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) [Part B and C]
- •-Have medical or surgical conditions in which lumbar puncture and or/catheter insertion is contraindicated
- •-Have any contraindication for magnetic resonance imaging (MRI) studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
- •Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) [Part C]
- •-Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen post treatment
研究者
相似试验
已完成
1 期
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT2080222069Eli Lilly Japan K.K.
已完成
1 期
Single Ascending Dose and Multiple Ascending Dose Phase I study of PXS-4728A Administered Orally in Healthy Adult Males.Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary diseaseRespiratory - Other respiratory disorders / diseasesCystic FibrosisACTRN12614001326684Pharmaxis Ltd.72
已完成
1 期
A study of the safety and pharmacokinetics and pharmacodynamics of the LOXL2 inhibitor PXS-5338K in healthy male subjects given single and repeated doses.ACTRN12617001444370Pharmaxis Ltd72
已完成
1 期
First-in-Human Study of RLYB116 in Healthy Participantscomplement mediated diseasesBlood - Haematological diseasesInflammatory and Immune System - Autoimmune diseasesACTRN12621001571864IPC Research, LLC89
已完成
1 期
A Randomized, Single-Dose and Multiple Dose Dose-Ranging Safety and Pharmacokinetics Study of Tacrolimus Powder for Inhalation in Healthy Adult SubjectsProphylactic therapy of organ rejection in patients receiving allogeneic lung transplantsRespiratory - Other respiratory disorders / diseasesInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12620000192987TFF Pharmaceuticals Australia Pty Limited64